  Identifying targets for personalized targeted therapy is the pathologist's
domain and a treasure. For decades, pathologists have had to learn, understand,
adopt and implement many new laboratory techniques as they arrived on the
scene. Pathologists successfully integrate the results of those tests into
final pathology reports that were, and still are, the basis of clinical
therapeutic decisions. The molecular methods are different but no more
difficult to comprehend in the era of "kit procedures". Pathologists have the
knowledge and expertise to identify particular gene mutations using the
appropriate molecular tests currently available. This review focuses on the
most important recent developments in KRAS mutation testing in metastatic
colorectal cancer (CRC), and shows that a pathologist is involved in 10 stages
of this procedure. Recent studies have shown that highly sensitive, simple,
reliable and rapid assays may significantly improve the identification of CRC
patients resistant to anti-EGFR therapy. Thus, direct sequencing does not seem
to be an optimal procedure of KRAS testing for clinical purposes. Twelve
currently available high-sensitivity diagnostic assays (with the CE-IVD mark)
for KRAS mutation testing are briefly described and compared. The suggested
pathology report content for somatic mutation tests is described. In
conclusion, evidence is presented that sending away paraffin blocks with tumor
tissue for KRAS mutation testing may not be in the best interest of patients.
Instead, an evidence-based approach indicates that KRAS mutation testing should
be performed in pathology departments, only with the use of CE-IVD/FDA-approved
KRAS tests, and with the obligatory, periodic participation in the KRAS EQA
scheme organized by the European Society of Pathology as an independent
international body.
